Related Experiment Videos
Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host
Insights
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) can cause severe respiratory infections in immunocompromised individuals. Ribavirin shows promise for treating these infections, warranting further investigation in this vulnerable population.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are common paramyxoviruses causing respiratory illness in children.
- While typically mild in immunocompetent hosts, these viruses can lead to severe, life-threatening lower respiratory tract infections in immunocompromised individuals.
- Immunocompromised patients, particularly bone marrow transplant recipients, face significant morbidity and mortality from RSV and PIV infections.
Purpose of the Study:
- To review the clinical manifestations and diagnostic approaches for RSV and PIV in immunocompromised hosts.
- To evaluate the potential therapeutic role of ribavirin in treating RSV and PIV infections in this vulnerable patient group.
- To advocate for the use of ribavirin in immunocompromised patients with RSV or PIV infections pending further clinical trials.
Main Methods:
- Review of existing literature on RSV and PIV epidemiology, clinical presentation, and diagnosis.
- Analysis of in vitro and clinical data regarding the efficacy of ribavirin against RSV and PIV.
- Assessment of the safety profile of ribavirin treatment.
Main Results:
- RSV and PIV infections present with upper and lower respiratory tract symptoms in immunocompromised hosts, with a higher incidence of severe complications.
- Rapid diagnostic tests are available for RSV, while PIV diagnosis often relies on slower culture methods.
- Ribavirin demonstrates in vitro efficacy against RSV and PIV and has shown benefit in infants with RSV, though trials in immunocompromised patients are lacking.
Conclusions:
- RSV and PIV infections pose a serious threat to immunocompromised individuals, necessitating effective treatment strategies.
- Given the in vitro activity and relatively benign nature of ribavirin, its use in immunocompromised patients with RSV or PIV is suggested.
- Further clinical trials are crucial to establish the definitive efficacy and safety of ribavirin in treating RSV and PIV in immunocompromised populations.
Abstract:
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are common causes of respiratory infections in immunocompetent children under the age of 6 years. These viruses belong to a family of enveloped single-stranded RNA viruses, the paramyxoviruses. The clinical manifestations in the normal host range from mild illness to severe croup, bronchiolitis, and pneumonia. After the age of 6 years, reinfections occur, but are characterized by diminishing frequency and severity. In contrast to the normal adult host, severe lower respiratory tract infection can occur in immunocompromised adults as well as children, with significant morbidity and mortality. Similar to the normal host, infection with RSV occurs in epidemics in the winter and spring, while PIV occurs throughout the year. Immunocompromised hosts often have upper respiratory tract symptoms similar to those experienced by normal hosts, as well as a higher incidence of lower respiratory tract symptoms and sinusitis. Lower respiratory tract infection can lead to respiratory failure and death, especially in bone marrow transplant recipients. The diagnosis of RSV and PIV depends on the analysis of specimens obtained from the respiratory tract. Rapid diagnostic tests are readily available for RSV and are less widely used for some of the PIV serotypes. Primary cultures are used for both viruses, but take several days to yield a positive result. Ribavirin, a broad-spectrum antiviral agent, is effective against RSV and PIV in vitro. Clinical trials have shown ribavirin to be of benefit in treating infants infected with RSV. However, clinical trials in immunocompromised patients infected with RSV or PIV have not been carried out. Since infection with RSV and PIV can be severe and life-threatening and treatment with ribavirin is relatively benign, it seems warranted to treat immunocompromised patients infected with RSV or PIV with ribavirin until otherwise proven unwarranted.